Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | FABP1 | P07148 | 1/20 | 0.38 |
| ▸ | FABP6 | P51161 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7448182 | 0.82 | MEN1 (0.50) | MEN1KMT2AMAPK10GFERKDR | |
| SCHEMBL28279163 | 0.80 | MEN1 (0.48) | MEN1KMT2AMAPK10GFERKDR | |
| SCHEMBL19581189 | 0.76 | MEN1 (0.48) | MEN1KMT2AMAPK10GFERKDR | |
| SCHEMBL1716509 | 0.75 | ALDH1A1 (0.43) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL9376222 | 0.75 | NPC1 (0.48) | MEN1KMT2AMAPK10GFERNPC1 | |
| SCHEMBL5309255 | 0.74 | MEN1 (0.42) | MEN1KMT2AMAPK10GFERKDR | |
| SCHEMBL17700145 | 0.74 | CXCR4 (0.47) | MEN1KMT2AMAPK10GFERNPC1 | |
| SCHEMBL19581195 | 0.72 | MEN1 (0.44) | MEN1KMT2AMAPK10GFERKDR | |
| SCHEMBL29794355 | 0.72 | CYP2C19 (0.47) | MEN1KMT2AMAPK10GFERNPC1 | |
| SCHEMBL17700558 | 0.72 | CYP2C19 (0.47) | MEN1KMT2AMAPK10GFERNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| CN-116003328-A | Diaryl hydantoin compounds | 加利福尼亚大学董事会 | 2023-04-25 | — | — | CN | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| CN-110003114-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2023-01-17 | — | — | CN | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-12 | — | — | US | disclosed |
| CN-110003114-A | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2019-07-12 | — | — | CN | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| CN-105037273-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2019-04-19 | — | — | CN | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| US-8183274-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2444085-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1893196-A4 | DIARYLHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2009-03-18 | — | — | EP | disclosed |
| CN-101222922-A | Diarylhydantoin compounds | UNIV CALIFORNIA (US) | 2008-07-16 | — | — | CN | disclosed |
| EP-1893196-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006124118-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MEN1 33/4885KMT2A 320/4885MAPK10 4143/4885 |
| US-20180086718-A1 | Diarylhydantoin Compounds | BPHL, AR, SHBG | MEN1 33/4885KMT2A 320/4885MAPK10 4143/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | MEN1 653/4885KMT2A 404/4885MAPK10 3042/4885 |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | MEN1 67/4885KMT2A 524/4885MAPK10 2342/4885 |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MEN1 33/4885KMT2A 320/4885MAPK10 4143/4885 |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MEN1 33/4885KMT2A 320/4885MAPK10 4143/4885 |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MEN1 33/4885KMT2A 320/4885MAPK10 4143/4885 |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MEN1 33/4885KMT2A 320/4885MAPK10 4143/4885 |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MEN1 33/4885KMT2A 320/4885MAPK10 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.